Michael Tattory

RedHill Biopharma Ltd. announced today the full Week 52 results for all subjects in the Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (MAP US study) and supportive topline results from the open-label extension Phase 3 study (MAP US2 study).

A phase I/II trial run by the Dutch company ProQR has found that its RNA therapy could significantly improve the vision of people with Leber’s congenital amaurosis, a rare genetic disease for which there is no treatment.

Reata Pharmaceuticals said Thursday it will pay AbbVie $330 million over the next two years to re-acquire most of the ex-U.S. rights for its leading drug candidates.

Motus GI, a medical technology company focussing on colonoscopy, has announced the first commercial placements of its Pure-Vu System as part of its initial U.S. market launch targeting early adopter hospitals.

Cerevance, a pharmaceutical company focusing on central nervous system diseases, has developed a new process for peering into the gene expression of specific brain cells. Their Nuclear Enriched Transcript Sort sequencing (NETSseq) platform can leverage a technique to specifically sort and isolate specific types of brain cells to more closely study each type.

Alkahest is a clinical stage company with multiple therapeutic candidates in Phase 2 trials. The company is hoping to develop a treatment for patients with Alzheimer’s but is taking a different path. Alkahest is looking at the plasma proteome and, specifically, how it changes with age.

One of the main barriers to medication adherence among diabetics is the painful, constant administration of insulin using a needle and syringes. Moreover, subcutaneous insulin administration has long been admonished for its slow onset of action. People living with this chronic condition need a convenient and efficient method of administering this crucial hormone. Biopharmaceutical company

Spring resident Leah Cravens wanted to have a baby. With her husband diagnosed with cystic fibrosis, rendering him infertile, an in vitro fertilization was her only choice. The problem? Chronic migraines have been plaguing Cravens for more than 20 years, the medicine for which would be unsafe during her pregnancy.

Jessica Reeder worries about ticks and the diseases they carry. She had Lyme disease, her brother had Lyme disease, and every fall her children come home from school with notes reminding parents to do a nightly tick check. Even in Philadelphia, where Reeder lives, the bloodsuckers lurk in the woods around the playground. Her family used

Dance BioPharma has joined the Bay Area exodus, but its story is unlike some of the more high-profile departures.

Data on the company’s pacemaker-neurostimulator combo are probably good enough to permit further development – but first the company wants to hook a partner.

Amid the debate about why insulin costs so much lies a second question: if the hormone can be delivered more efficiently, will people with diabetes need less insulin? It’s not just a question that’s come up in the era of the artificial pancreas, as people with type 1 diabetes (T1D) work with technology that uses

Due to the need for chemotherapy and the risks caused by allogeneic stem cell transplants in Fanconi anaemia patients, Rocket Pharma has developed gene therapy candidate RP-L102, which doesn’t need conditioning and corrects the gene mutation underlying Fanconi. Rocket CEO Guarav Shah explains RP-L102’s mechanism of action, as well as how the company is working

Drug resistance presents a significant challenge to oncologists. Therapies that were once capable of destroying the tumor are rendered ineffective once one resistant cancer cell begins to multiply. Part of the challenge of developing effective cancer therapies is tackling the multiple pathways by which drug resistance arises. Isaac Israel, CEO of Kitov Pharmaceuticals, and his

Dance Biopharm today said it rebranded as Aerami Therapeutics and will move its headquarters to Durham, N.C. The rebranding comes as the company seeks strategic partners for its Dance 501 inhaled human insulin. The company also hopes the rebranding will help progress into pivotal registration studies and expand to include inhaled therapeutics for endocrinology diseases.

In the not very distant future, Type 2 diabetes patients may have an option to inhale insulin that acts faster and lasts longer than Lilly’s injected insulin Humalog or its generic, lispro, the current standard treatment. Durham-based Aerami Therapeutics, which changed its name from Dance Biopharm Holdings Inc. on Wednesday, reports that data from its Phase 2 clinical

Just over 20 years ago, a Lyme disease vaccine called LYMErix was approved for sale in the United States. Researchers designed the vaccine to prevent the transmission of the tick-borne pathogen Borellia burgdorferi, which spurs a bacterial infection that can cause fever, headaches, and joint pain if left untreated.

Data from a phase 2a clinical trial of DUR-928, an endogenous, small-molecule new chemical entity, for patients with alcoholic hepatitis demonstrated that the treatment led to greater reductions from baseline in bilirubin and MELD and improved Lille scores compared with a historical control group from a University of Louisville alcoholic hepatitis study, according to a

Nurix Therapeutics is harnessing the body’s natural process for controlling protein levels to target and degrade proteins that drive cancer and other diseases. Its small molecule therapies control key enzymes responsible for protein breakdown and can be used to modulate the levels of proteins within cells. The company believes it can leverage the approach to

DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output. DNA-encoded library (DEL) screens blow conventional high throughput screening techniques out of the water when it comes to library size and diversity,

OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.

OncoCyte’s newly appointed CEO Ronald Andrews is making good on a promise for more transparency in the company. Investors and analysts witnessed this new level of transparency first hand during a detailed conference call the Alameda, CA-based company held concerning its plan for acquiring Razor Genomics.

Orchestra BioMed said yesterday that it received the CE Mark for its Moderato implantable pulse generator system for BackBeat cardiac neuromodulation therapy (CNT), just nine days after naming a new chief medical officer. BackBeat therapy is a bioelectronic treatment designed to lower blood pressure while modulating the autonomic nervous system. The Moderato implantable device is

Orchestra BioMed, a company out of New Hope, Pennsylvania, won the European CE Mark of approval for the Moderato implantable pulse generator which delivers Orchestra’s unique BackBeat Cardiac Neuromodulation Therapy (CNT) to treat hypertension. High blood pressure is typically treated using drugs, but BackBeat allows even existing cardiac implants to deliver therapy in a novel

Sometimes things don’t go your way in the biotech industry. The CEO of Valneva, Thomas Lingelbach, shared his experience of migrating from big pharma to biotech, and how his first biotech company weathered phase III failures to develop vaccines for neglected diseases.

A year into his cancer treatment, Stephen heard about the benefits of medical marijuana and CBD oil, but it has proven difficult to get.

You’ve invested millions of dollars, spent over a decade conducting trials and it’s only when you reach the final phase that you realize your product doesn’t even work. That can be the unfortunate reality for vaccine development. Few understand this better than Thomas Lingelbach, CEO of Valneva, a company focused on the development of innovative